The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression DOI
Muhammad Youshay Jawad, Joshua D. Di Vincenzo, Sebastian Badulescu

et al.

Neuropharmacology, Journal Year: 2022, Volume and Issue: 223, P. 109299 - 109299

Published: Nov. 3, 2022

Language: Английский

Role of oxidative phosphorylation in the antidepressant effects of arketamine via the vagus nerve-dependent spleen-brain axis DOI Creative Commons
Lijia Chang, Wei Yan, Youge Qu

et al.

Neurobiology of Disease, Journal Year: 2024, Volume and Issue: 199, P. 106573 - 106573

Published: June 18, 2024

Arketamine, the (R)-enantiomer of ketamine, exhibits antidepressant-like effects in mice, though precise molecular mechanisms remain elusive. It has been shown to reduce splenomegaly and depression-like behaviors chronic social defeat stress (CSDS) model depression. This study investigated whether spleen contributes arketamine CSDS model. We found that splenectomy significantly inhibited arketamine's CSDS-susceptible mice. RNA-sequencing analysis identified oxidative phosphorylation (OXPHOS) pathway prefrontal cortex (PFC) as a key mediator splenectomy's impact on effects. Furthermore, oligomycin A, an inhibitor OXPHOS pathway, reversed suppressive Specific genes within pathways, such COX11, UQCR11 ATP5e, may contribute these inhibitory Notably, transforming growth factor (TGF)-β1, along with appears modulate Additionally, SRI-01138, agonist TGF-β1 receptor, alleviated Subdiaphragmatic vagotomy also counteracted These findings suggest PFC play significant roles arketamine, mediated through spleen-brain axis via vagus nerve.

Language: Английский

Citations

7
Transforming growth factor-β1 mediates the beneficial effects of arketamine on demyelination and remyelination in the brains of cuprizone-treated mice DOI Creative Commons

Mingming Zhao,

Tingting Zhu, Dan Xu

et al.

European Journal of Pharmacology, Journal Year: 2024, Volume and Issue: 985, P. 177096 - 177096

Published: Nov. 3, 2024

The novel antidepressant arketamine, the (R)-enantiomer of ketamine, has been shown to ameliorate demyelination and facilitate remyelination in brains cuprizone (CPZ)-treated mice. However, mechanisms behind its effects remain unclear. Given role transforming growth factor β1 (TGF-β1) arketamine's antidepressant-like effects, we examined whether TGF-β1 also plays a on CPZ-treated Additionally, investigated intranasal these Repeated intermittent administration arketamine (10 mg/kg/day, twice weekly for last 2-weeks) attenuated corpus callosum (CC) CPZ (6 weeks)-treated Furthermore, pretreatment with RepSox mg/kg/day), an inhibitor TGF-β receptor 1, significantly blocked beneficial CC repeated (3.0 μg/kg/day, 2 weeks) ameliorated facilitated These data suggest that can mitigate facilitates mice through TGF-β1-dependent mechanism.

Language: Английский

Citations

6
Role of neurotrophic and growth factors in the rapid and sustained antidepressant actions of ketamine DOI Creative Commons
Satoshi Deyama, Katsuyuki Kaneda

Neuropharmacology, Journal Year: 2022, Volume and Issue: 224, P. 109335 - 109335

Published: Nov. 17, 2022

Language: Английский

Citations

28
Depression and antidepressant effects of ketamine and its metabolites: The pivotal role of gut microbiota DOI
Hao Hua, Chaoli Huang, Hanyu Liu

et al.

Neuropharmacology, Journal Year: 2022, Volume and Issue: 220, P. 109272 - 109272

Published: Sept. 25, 2022

Language: Английский

Citations

27
The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression DOI
Muhammad Youshay Jawad, Joshua D. Di Vincenzo, Sebastian Badulescu

et al.

Neuropharmacology, Journal Year: 2022, Volume and Issue: 223, P. 109299 - 109299

Published: Nov. 3, 2022

Language: Английский

Citations

24